Detalhe da pesquisa
1.
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
Haematologica
; 2023 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855051
2.
Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.
Exp Mol Pathol
; 110: 104260, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31082388
3.
A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
J Natl Compr Canc Netw
; 16(11): 1311-1320, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442732
4.
A Strategy for Changing Adherence to National Guidelines for Decreasing Laboratory Testing for Early Breast Cancer Patients.
WMJ
; 117(2): 68-72, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30048575
5.
Fewer Reoperations After Lumpectomy for Breast Cancer with Neoadjuvant Rather than Adjuvant Chemotherapy: A Report from the National Cancer Database.
Ann Surg Oncol
; 24(6): 1507-1515, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28062931
6.
21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
Breast Cancer Res Treat
; 159(2): 315-26, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27507245
7.
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
Clin Cancer Res
; 29(23): 4808-4821, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37728879
8.
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Cancer Res Commun
; 3(7): 1335-1349, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37497337
9.
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.
Blood Cancer J
; 12(2): 25, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35105854
10.
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
Clin Cancer Res
; 28(5): 972-983, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34980601
11.
External Validation of AJCC Eighth Edition of Non-small-cell Lung Cancer Staging Among African Americans.
Clin Lung Cancer
; 22(3): e371-e378, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32713769
12.
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
Oncoimmunology
; 10(1): 1928365, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34350060
13.
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Mol Cancer Res
; 19(2): 249-260, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33154093
14.
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
JCO Precis Oncol
; 52021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34476329
15.
Utilization of Surgery and Its Impact on Survival in Patients With Early Stage Small-cell Lung Cancer in the United States.
Clin Lung Cancer
; 21(2): 186-193.e2, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31606340
16.
Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
Clin Breast Cancer
; 20(4): e433-e438, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32234363
17.
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
J Hematol Oncol
; 13(1): 148, 2020 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33148342
18.
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.
Blood Adv
; 4(14): 3391-3404, 2020 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32722783
19.
A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).
Clin Breast Cancer
; 19(3): e481-e493, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30878300
20.
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.
Mol Cancer Ther
; 18(2): 346-355, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425131